This is the first Vietnamese vaccine allowed to go for human trial. The vaccine is being submitted for conditional emergency licensing.

Professor Truong Viet Dung, Head of the National Ethics Council of the Ministry of Health said the Council approved the testing results on humans with Nanocovax vaccine for its safety and immunogenicity in phase 3A. Combining the results of phase 2 and midterm phase 3A shows that, on average, antibody levels in the blood increased more than 200 times after 42 days of vaccination. The sero-conversion rate reached 99.2%. Regarding the side effects after injection such as pain at the injection site, fatigue, joint pain, and nausea; they are mostly mild.

Dossiers of Nanocovax vaccine trials have been submitted to the Advisory Council of the Ministry of Health for consideration for conditional emergency licensing.

At an online workshop on Vietnamese vaccines, Doctor Nguyen Huu Huan of the IGY Life Sciences and a Professor at Arizona University said Nanocovax meets all criteria for emergency licensing.